Talk:Unity Biotechnology

Latest comment: 3 years ago by Ferkijel in topic One proposed change

Request edit

edit

As an employee of Unity Biotechnology, I am proposing two changes to the current description of the company based on publicly available information.

1- the page currently states that has a product "in Phase I clinical trials as of September 2018" (second paragraph) Actually, the Phase 1 trial was initiated in June 2018, as reported on FightAging.org[1]. The company also issued a press release announcing the trial initiation. [2]I propose that this date be updated accordingly to state "as of June 2018..." 2- the page states that "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending life span." (paragraph 1) As noted in the company's S-1 SEC filing[3], the company's mission is to "extend human healthspan" not life span. As such, I propose replacing "life span" with "healthspan" so that the sentence reads: "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending healthspan."Bluealg (talk) 21:30, 14 November 2018 (UTC)Reply

References

Reply 14-NOV-2018

edit

   Edit request implemented  

  • Healthspan is a neologism, so that lead statement has been omitted from the article, per MOS:NEO.  Spintendo  00:24, 15 November 2018 (UTC)Reply

One proposed change

edit
  • Information to be added or removed: Remove "Unity Biotechnology shares dropped over 60 per cent on August 17, 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101 in patients with moderate-to-severe painful osteoarthritis."
  • Explanation of issue: A single day stock price is unusual for Wikipedia. Should all stock price changes be included in Unity's Wikipedia page?
  • References supporting change: https://finance.yahoo.com/quote/ubx?ltr=1

Jw126 (talk) 23:18, 26 January 2021 (UTC)Reply

I wouldn't say it's unusual to document a drop or rise in price that received significant coverage in reliable, independent sources. Nearlyevil665 (talk) 18:22, 3 February 2021 (UTC)Reply

Their stock value as of today (30 March 2021) still has not recovered, and it trades at approximately half the price of that from before the UBX0101 clinical-trial announcement (USD 5.5 today vs USD 12.4 on 14 August 2020). We can wait and see if the stock recovers, a time when we can mark the loss as not signficant in the medium-term and remove the phrase from the article. In the meantime it can remain there unless other editors disagree. Ferkijel (talk) 10:29, 30 March 2021 (UTC)Reply